BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32825798)

  • 21. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
    Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell.
    Mese H; Sasaki A; Alcalde RE; Nakayama S; Matsumura T
    Chemotherapy; 1998; 44(6):414-20. PubMed ID: 9755302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
    Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
    Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M; Hashimoto K; Shimada J; Sakagami H
    Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
    Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
    Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
    Suzuki M; Shinohara F; Nishimura K; Echigo S; Rikiishi H
    Int J Oncol; 2007 Dec; 31(6):1449-56. PubMed ID: 17982671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy.
    Li S; Wu Y; Ding Y; Yu M; Ai Z
    J Cell Physiol; 2018 Dec; 233(12):9416-9425. PubMed ID: 30054909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptation to Endoplasmic Reticulum Stress Enhances Resistance of Oral Cancer Cells to Cisplatin by Up-Regulating Polymerase η and Increasing DNA Repair Efficiency.
    Chen CY; Kawasumi M; Lan TY; Poon CL; Lin YS; Wu PJ; Chen YC; Chen BH; Wu CH; Lo JF; Weng RR; Sun YC; Hung KF
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p.
    Ma SQ; Wang YC; Li Y; Li XY; Yang J; Sheng YM
    J Biol Regul Homeost Agents; 2020; 34(6):1993-2001. PubMed ID: 33191714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
    Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
    Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation.
    Lin F; Gao L; Su Z; Cao X; Zhan Y; Li Y; Zhang B
    Oncol Rep; 2018 Jul; 40(1):179-194. PubMed ID: 29781035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
    Naik PP; Mukhopadhyay S; Panda PK; Sinha N; Das CK; Mishra R; Patil S; Bhutia SK
    Cell Prolif; 2018 Feb; 51(1):. PubMed ID: 29171106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
    Lu M; Wang C; Chen W; Mao C; Wang J
    DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxicity of thymoquinone alone or in combination with cisplatin (CDDP) against oral squamous cell carcinoma in vitro.
    Alaufi OM; Noorwali A; Zahran F; Al-Abd AM; Al-Attas S
    Sci Rep; 2017 Oct; 7(1):13131. PubMed ID: 29030590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of cell death by combination treatment with cisplatin and 5-fluorouracil in a human oral squamous cell carcinoma cell line.
    Okamura M; Kobayashi M; Suzuki F; Shimada J; Sakagami H
    Anticancer Res; 2007; 27(5A):3331-7. PubMed ID: 17970078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma.
    Endo K; Ueno T; Kondo S; Wakisaka N; Murono S; Ito M; Kataoka K; Kato Y; Yoshizaki T
    Cancer Sci; 2013 Mar; 104(3):369-74. PubMed ID: 23216802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
    Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-155 Inhibitor-Laden Exosomes Reverse Resistance to Cisplatin in a 3D Tumor Spheroid and Xenograft Model of Oral Cancer.
    Sayyed AA; Gondaliya P; Mali M; Pawar A; Bhat P; Khairnar A; Arya N; Kalia K
    Mol Pharm; 2021 Aug; 18(8):3010-3025. PubMed ID: 34176265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
    Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
    Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.